Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £12 | £12 | £11 | £11 |
| % Growth | 5% | 3.3% | 3.2% | – |
| Cost of Goods Sold | £7 | £6 | £6 | £6 |
| Gross Profit | £6 | £5 | £5 | £5 |
| % Margin | 45.3% | 46.2% | 44.4% | 43.7% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £3 | £3 | £3 | £3 |
| Sales & Mktg Exp. | £3 | £3 | £3 | £2 |
| Other Operating Expenses | £0 | £0 | -£0 | £0 |
| Operating Expenses | £3 | £3 | £3 | £3 |
| Operating Income | £3 | £3 | £2 | £2 |
| % Margin | 20.5% | 21.9% | 19% | 18% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | £2 | £2 | £2 | £2 |
| Tax Expense | £1 | £1 | £0 | £0 |
| Net Income | £2 | £2 | £1 | £1 |
| % Margin | 14.9% | 14.3% | 13% | 12.4% |
| EPS | 4.1 | 3.77 | 3.31 | 3.06 |
| % Growth | 8.8% | 13.9% | 8.2% | – |
| EPS Diluted | 4.1 | 3.77 | 3.31 | 3.06 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £1 | £1 | £0 | £0 |
| EBITDA | £3 | £3 | £2 | £2 |
| % Margin | 21.2% | 25.2% | 19.9% | 21.7% |